Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senator Tells FDA To Create ‘Red Team’ For Regulatory Streamlining

This article was originally published in The Pink Sheet Daily

Executive Summary

HELP Committee Chairman Lamar Alexander wants FDA to suggest regs and other bureaucratic requirements that are hindering productivity as part of medical innovation effort.

You may also be interested in...



Califf Nomination Adds New Dynamic, Maybe New Provisions, To FDA Reform Bills

Senate legislation may be influenced by movement to push through Califf’s nomination for FDA commissioner.

Cures Excitement May Wane While Senate Works

Senate Health Committee continues work on its own 21st Century Cures-related legislation, meaning the newly passed House bill will be out of the spotlight for a bit.

FDA Central Review Likely For Novel Surrogate Endpoints

CDER’s Woodcock says accelerated approval requirements in 21st Century Cures legislation could create a process akin to how FDA handles breakthrough designations.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS078422

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel